deltatrials
Unknown NA INTERVENTIONAL NCT00380172

Long-Term Efficacy in AMD of Rheopheresis in North America

A Multicenter, Open Label, Prospective Study to Determine Safety and Efficacy Over an Additional 12-Month Period With Non-Exudative Age-Related Macular Degeneration (With Follow-on to 12-Months)

Sponsor: OccuLogix

Conditions Macular Degeneration
Interventions Rheopheresis blood filtration
Updated 5 times since 2017 Last updated: Sep 21, 2006 Started: Oct 31, 2005 Completion: Oct 31, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Macular Degeneration and is currently ongoing. OccuLogix leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jan 2021 · 48 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 12 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown NA

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown NA

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown NA

    Status: Unknown Status → Unknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status NA

  5. Jan 2017 — Jan 2021 [monthly]

    Unknown Status NA

    First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • OccuLogix
Data source: OccuLogix

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations